Microbiome therapy for cancer! The treatment of recurrent glioblastoma may be a new hope.

Glioblastoma is an invasive form of brain cancer and there is no cure.
ENTEROME, a clinical-phased biopharmaceutical company focused on developing new therapies using knowledge of the microbiome-immune inflammatory axis, announced today that it has begun its first clinical trial using OncoMimic-based cancer immunotherapy EO2401.
Phase I/II Clinical Trials (ROSALIE) will study the effectiveness and safety of EO2401 joint immunoostaine inhibitors in the treatment of recurrent glioblastoma. Preliminary clinical data from the
ROSALIE study are expected to be published in 2022.
EO2401 is an immuno-tumor candidate derived from Enterome's revolutionary OncoMimic platform.
OncoMimics is a microbial-derived peptide antigen that simulates tumor cell expression.
these antigens trigger memory T-cell activation against gut bacteria and can trigger an lethal immune response to tumor cells.
the first clinical trial of EO2401 (ROSALIE, NCT04116658) is a multicenter, open-label I/II study designed to assess the safety, tolerance, immunogenicity, and initial efficacy of its combination with checkpoint inhibitors in the treatment of glioblastoma.
is expected to recruit 32 patients in 10 clinical centers in Europe and the United States. Professor Wolfgang Wick, head of the Department of Neurology at the University of Heidelberg in Germany,
, is the lead researcher at ROSALIE. Professor
Wolfgang Wick is a world-renowned neurooncologer with extensive clinical research experience in the field of primary and recurrent brain tumors.
.